随着抗HER2治疗技术的不断进步，从新辅助治疗到辅助治疗策略日益精细化和个体化。尽管已取得显著疗效，但如何精准指导后续治疗、优化治疗方案 ...

这是德曲妥珠单抗在国内获批的第四项适应症，此前已在国内获批三项适应症： 单药治疗既往接受过一种或一种以上抗 HER2 治疗、不可切除或转移性 ...

Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...

HER2-targeted therapies, originally developed for breast cancer, may also benefit patients with rare bile duct cancer and ...

overexpression of HER2/neu confirmed by FISH amplification of HER2; measurable or evaluable disease documented by imaging procedures according to the Response Evaluation Criteria in Solid Tumors ...

The newly reported studies demonstrated that the antibodies, in a T cell engager format, can effectively kill cancer cells expressing relevant HER2 mutations both in vitro, and in a mouse ...

HER2/NEU targeted therapy September 22, 2017 February 4, 2022 Opdivo (nivolumab) Hepatocellular carcinoma previously treated with sorafenib September 22, 2017 July 23, 2021 Opdivo (nivolumab) ...

Drugs designed to target HER2-postive breast cancer could also benefit some patients with bile duct cancer, according to results of a patient trial to be presented on Thursday at the 36th EORTC ...

An early-stage HER2-positive (HER2+) breast cancer is always a shock, but today’s treatment options should give you hope. Over the past 2 decades, advances in medicine have brought us new ...

HER2 is a protein that’s on the outside of all breast cells, whether they’re normal or cancerous. But when your breast cancer is described as HER2-positive, it means the cancer cells have more ...

Caption The traditional HER2 score evaluation depends on manual inspection of tissue slides by pathologists. Our presented methodology introduces automated HER2 scoring using pyramid sampling and ...